PTC Therapeutics Inc. priced its previously announced public offering of 4 million shares at $27.04 per share.

Credit Suisse and Citigroup are acting as lead book-running managers for the offering, which is expected to close by April 3.

RBC Capital Markets is acting as a book-running manager.

The South Plainfield, N.J.-based biotechnology company has granted the underwriters a 30-day option to acquire an additional 600,000 shares.